Clinical trials in cervical intraepithelial neoplasia: Balancing the need for efficacy data with patient safety

Journal of Lower Genital Tract Disease

Volumn 6, Issue 4, 2002, Pages 206-211

  Silverman, Michael H ^a   Hedley, Mary Lynne ^b   Petry, K Ulrich ^c   Weber, Jeffrey S ^d  

^a BioStrategics Consulting Ltd   (United States)

^b ZYCOS Inc   (United States)

^c Frauenklinik der Medizischen Hochschule   (Germany)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cervical intraepithelial neoplasia; Clinical trials; Natural history

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOLOGIC AGENT;

CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER SCREENING; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DATA ANALYSIS; DATA BASE; FEMALE; FOLLOW UP; HEALTH CARE COST; HISTORY; HUMAN; LONG TERM CARE; MEDICAL LITERATURE; PATIENT CARE; POPULATION; PREGNANCY; REVIEW; SAFETY; STATISTICAL SIGNIFICANCE; TUMOR BIOPSY; UTERINE CERVIX CARCINOMA IN SITU;

EID: 0036775514     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/00128360-200210000-00002     Document Type: Review

References (25)

1. Hengge UR, Benninghoff B, Ruzicka T, Goos M. Topical immunomodulators-progress towards treating inflammation, infection, and cancer. Lancet Infect Dis 2001;1:189-98.
2. Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J Antimicr Chemo 2001;48:751-5.
3. Diaz-Arrastia C, Arany I, Robazetti SC, Dinh TV, Gatalica Z, Tyring SK, et al. Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%. Clin Cancer Res 2001;7:3031-3.
4. Romney SL, Ho GY, Palan PR, Basu J, Kadish AS, Klein S, et al. Effects of β-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol Oncol 1997;65:483-92.
5. Bell MC, Crowley-Nowick P, Bradlow HL, Sepkovic DW, Schmidt-Grimminger D, Howell P, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 2000;78:123-9.
6. Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E, et al. Cell mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998;4:2103-9.
7. Jabbar IA, Fernando GJ, Saunders N, Aldovini A, Young R, Malcolm K, et al. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 2000;18:2444-53.
8. Lacey CJ, Thompson HS, Monteiro EF, O'Neill T, Davies ML, Holding FP, et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 1999;179:612-8.
9. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithalial neoplasia who are HPV 16 positive. Clin Cancer Res 2000;6:3406-16.
10. Hannigan E. Cervical cancer in pregnancy. Clin Obstet Gynecol 1990;4:837-45.
11. Ueki M, Ueda M, Kumagai K, Okamoto Y, Noda S, Matsuoka M, et al. Cervical cytology and conservative management of cervical neoplasias during pregnancy. Inter J Gynecol Path 1995;1:63-9.
12. LaPolla JP, O'Neill C, Wetrich D. Colposcopic management of abnormal cervical cytology in pregnancy. J Repro Med 1988;3:301-6.
13. DePetrillo AD, Townsend D, Morrow CP, Lickrish GM, DiSaia PJ, Roy M. Colposcopic evaluation of the abnormal Papanicolaou test in pregnancy. Amer J Obstet Gynecol 1975;4:441-5.
14. Kohan S, Beckman EM, Bigelow B, Klein SA, Douglas GW. The role of colposcopy in the management of cervical intraepithelial neoplasia during pregnancy and postpartum. J Repro Med 1980;5:279-84.
15. McDonnell JM, Mylotte MJ, Gustafson RC, Jordan JA. Colposcopy in pregnancy. A twelve year review. Brit J Obstet Gynaecol 1981;4:414-20.
16. Hacker NF, Berek JS, Lagasse LD, Charles EH, Savage EW, Moore JG. Carcinoma of the cervix associated with pregnancy. Obstet Gynecol 1982;6:735-46.
17. Woodrow N, Permezel M, Butterfield L, Rome R, Tan J, Quinn M. Abnormal cervical cytology in pregnancy: experience of 811 cases. Austral New Zeal J Obstet Gynaecol 1998;2:161-5.
18. Roberts CH, Dinh TV, Hannigan EV, Yandell RB, Schnadig VJ. Management of cervical intraepithelial neoplasia during pregnancy: a simplified and cost-effective approach. J Lower Gen Tract Dis 1998;2:67-70.
19. Yost NP, Santoso JT, McIntire DD, Iliya FA. Postpartum regression rates of antepartum cervical intraepithelial neoplasia II and III lesions. Obstet Gynecol 1999;93:359-62.
20. Connor JP. Noninvasive cervical cancer complicating pregnancy. Obstet Gynecol Clin N Am 1998;2:331-42.
21. Palle C, Bangsboll S, Andreasson B. Cervical intraepithelial neoplasia in pregnancy. Acta Obstet Gynecol Scand 2000;79:306-10.
22. Fu Y, Reagan JW, Richart RM. Definition of precursors. Gynecol Oncol 1981;2:S220-1.
23. Bibbo M, Dytch HE, Alenghat E, Bartels PH, Wied GL. DNA ploidy profiles as prognostic indicators in CIN lesions. Amer J Clin Path 1998;3:261-5.
24. Remmink AJ, Walboomers J, Helmerhorst T, Voorhorst F, Rozendaal L. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Inter J Cancer 1995;3:306-11.
25. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20-5.